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Objective: Impaired insight is an important and prevalent symptom of
psychosis. It remains unclear whether cognitive disturbances hamper
improvements in insight. We investigated the neurocognitive, social
cognitive, and clinical correlates of changes in insight.
Method: One hundred and fifty-four patients with a psychotic disorder
were assessed at baseline (T0) and after three years (T3) with the
Birchwood Insight Scale, the Positive And Negative Syndrome Scale,
measures of neurocognition and social cognition. Linear regression
analyses were conducted to examine to what extend neurocognition,
social cognition, clinical symptoms and phase of illness could uniquely
predict insight change. Subsequently, changes in these factors were
related to insight change.
Results: Better neurocognitive performance and fewer clinical
symptoms at baseline explained insight improvements. The additional
effect of clinical symptoms over and above the contribution of
neurocognition was significant. Together, these factors explained 10%
of the variance. Social cognition and phase of illness could not predict
insight change. Changes in clinical symptoms, but not changes in
neurocognitive performance were associated with insight change.
Conclusion: Neurocognitive abilities may predict, in part, the
development of insight in psychosis.
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Significant outcomes
• In a longitudinal design, neurocognition and clinical symptoms at baseline were uniquely related to
insight change after 3 years.
• Changes in clinical symptoms, but not changes in neurocognitive performance, were related to insight
change.
• Social cognition and phase of illness were not related to insight change.
Limitations
• A substantial subgroup did not participate in the study at follow-up.
• The assessment of social cognition and insight was limited.
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Introduction
Impaired insight, or unawareness of illness, is a
highly prevalent symptom of patients with a psy-
chotic disorder (1). Insight can be studied as a set
of descriptive beliefs and as a personal narrative
(2). In the current study, insight was studied as a
set of descriptive beliefs, including the following
aspects: i) awareness of illness, (ii) need for treat-
ment and (iii) relabelling of symptoms (3).
Impaired insight has adverse consequences on
outcomes of the disease, including functional
outcome, treatment adherence and re-admissions
(4–6). Multiple factors have been associated with
reduced insight, including neurocognitive impair-
ment, social cognition and clinical symptoms (7,
8). However, the majority of the studies investigat-
ing insight applied a cross-sectional design, leaving
the question whether the above factors contribute
to the course of insight over time unanswered. This
may be particularly relevant information for clini-
cians to be able to develop treatment strategies to
improve insight.
Of the neurocognitive domains, executive
impairment (working memory, reasoning/problem
solving) seems to contribute mostly to poor insight
in psychotic disorders, although in schizophrenia,
impairments in multiple domains of neurocogni-
tion (i.e. verbal learning and memory, attention/
vigilance) have been related to insight (7). Only a
few studies have investigated the course of insight
longitudinally. Parellada et al. demonstrated that
cognitive impairments predicted several aspects of
insight after two years (9). However, their assess-
ment did not include all of the neurocognitive
domains known to be impaired in schizophrenia
(10). A second study failed to find a significant
effect of neurocognition on future insight (11). In a
third study, patients with improved insight were
found to have better cognitive performance after
six months on some tasks, but not all (12). How-
ever, these findings may have been the result of
their inclusion of medication-na€ıve patients with a
first psychotic episode at baseline. Therefore,
although it has been suggested that cognitive
impairments limit the response to psychosocial
treatment in general (13), it has not yet been
addressed adequately whether this applies to
insight improvement as well.
Previously, we demonstrated that social cogni-
tion and clinical symptoms are both uniquely
related to level of insight, irrespective of neurocog-
nitive functioning; interestingly, phase of illness
moderated this effect (14). Taking these findings
into account, it is interesting to study whether neu-
rocognition, social cognition, clinical symptoms
and phase of illness are also predictive of changes
in insight. In addition, it is not known whether
changes in these factors fluctuate with changes in
insight change. Increases in severity of clinical
symptoms have been found to be associated with
decreases in insight, but only in patients with
recent onset psychosis (15).
Aims of the study
In the current study, we investigated factors associ-
ated with change in insight over time in a longitu-
dinal design. We expected that neurocognition and
social cognition would explain changes in insight
over time. We also investigated whether changes in
neurocognition, social cognition, clinical symp-
toms and phase of illness were associated with
changes in insight.
Material and methods
Participants
Two hundred and seventy patients with psychotic
disorders (predominantly schizophrenia) were
assessed with the Birchwood Insight Scale at base-
line (see Assessments). This was a subsample of the
patient population participating in the GROUP
project (16). The GROUP project is a large-scale
multicentre study that investigates the vulnerability
and protective factors for i) the development of a
psychotic disorder and ii) the variation of the
course of illness. Two of four centres participated
in the insight study (Amsterdam and Utrecht).
Diagnoses were confirmed using the Comprehen-
sive Assessment of Symptoms and History (17). To
maximize uniformity in experimental procedures
and experimenter behaviour, all interviewers
received extensive training. Interviewers were
research assistants, psychologists, psychiatrists,
nurses and PhD students. The procedure of
recruitment, informed consent, assessment instru-
ments, assessment training, approval by an accred-
ited Medical Ethics Review Committee and
population characteristics have been described in a
previous report on the project (13).
Assessments
Insight. Insight was assessed using two measures.
From the Positive And Negative Syndrome Scale
(PANSS) (18), a semistructured interview consist-
ing of 30 items, we used item G12 (Poor Judge-
ment and Insight). Scores on the PANSS range
from 1 (absent) to 7 (extremely severe). Secondly,
we used the Birchwood Insight Scale (BIS) (19).
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The BIS is a short self-rating questionnaire that
consists of eight questions addressing the three
components of insight in psychosis (Awareness of
Illness, Need for Treatment and Relabeling of
Symptoms). The BIS total score ranges from 0 to
12, with higher scores indicating better insight. For
insight, as well as neurocognition, social cognition
and clinical symptoms, composite measures were
created (see Statistical analysis). For insight, the
composite measure consisted of the PANSS item
G12, and the BIS.
Neurocognition. The neurocognitive measures used
in the GROUP study have been described in detail
elsewhere (20). The following tasks were adminis-
tered: Continuous Performance Test-HQ (CPT-
HQ) (attention/vigilance), Response Set-shifting
Task (RST) (reasoning and problem solving), short
form of the Wechsler Adult Intelligence Scale–III
(WAIS-III) containing the subtests Block Design
(reasoning and problem solving), Digit Symbol
(processing speed), Arithmetic (working memory)
and Information (verbal comprehension) (21),
Word Learning Task (WLT) immediate recall and
delayed recall (verbal learning and memory) (22).
Educational degree was assessed using nine catego-
ries, zero being the lowest (no education) and eight
being the highest (academic degree) (23). The
parameters used for neurocognition were similar
as in our previous study (14), with a few excep-
tions. For the CPT-HQ, two parameters were cre-
ated: CPT variance and CPT performance index.
For CPT variance, or intraindividual variability
(24), the standard deviation of the subject’s mean
response time on the hit trials was used. CPT per-
formance index consisted of an efficiency score
[(accuracy/reaction time) 9 1000], in which accu-
racy was measured as the total number of hits
(range, 0–28) minus the total number of errors
(range, 0–28), divided by 28. The RST parameter
was based on the subjects’ accuracy during the
experimental condition, during which the subject
has to find the alternated response rule. For all
neurocognitive tests, higher scores indicated better
performances, except for CPT variance.
Social Cognition. For social cognition, the
Degraded Facial Affect Recognition task (emotion
perception) (25) and the Hinting Task (Theory of
Mind) (26) were used. Higher scores on the
measures of social cognition reflected better per-
formances. The Hinting Task was measured at
baseline only.
Clinical Symptoms. Current symptom severity was
measured with the PANSS. Items on the PANSS
incorporate the behavioural effect of the symp-
toms, as well as their severity. Interrater reliability,
evaluated with ICC, was found to be high for the
positive subscale, the negative subscale and total
PANSS score (0.957, 0.911 and 0.946, respectively)
(16).
As in our earlier study (14), we calculated a
mean score of the subject’s ratings on the eight
remission items (27). These items include: delu-
sions (P1), conceptual disorganization (P2), hallu-
cinatory behaviour (P3), blunted affect (N1), social
withdrawal (N4), and lack of spontaneity (N6),
mannerisms/posturing (G5) and unusual thought
content (G9).
Phase of Illness. Phase of illness was divided into
recent onset psychosis and multiple or chronic psy-
chosis. Recent onset psychosis was defined as
follows: a first psychotic episode during the year
prior to the baseline assessment. All other patients
were characterized as having ‘multiple episode or
chronic psychosis’.
Statistical Analysis
Normality was checked for all variables. If neces-
sary, variables were transformed to approximate
normality using logarithmic or square root trans-
formation. Subsequently, a composite measure
was created for the insight measures at baseline
and follow-up. As in our previous study, the scores
on the G12 and BIS were transformed into
z-scores, based on the mean and standard devia-
tion of the baseline assessment (14). Insight change
was computed by subtracting the insight composite
score at baseline from the insight composite score
at follow-up. Thus, higher scores at insight change
reflect more insight improvement. A paired t-test
was used to investigate differences between base-
line and follow-up insight.
Next, composite scores were created for base-
line neurocognition, cognition and clinical symp-
toms. The composite score included all test
scores of each of the abovementioned factors
(see Method and materials: Assessments). For
neurocognition and social cognition, this was
carried out by transforming all the raw scores
into z-scores, using the mean and standard devi-
ations from the patient population included at
baseline (n = 270). For neurocognition, the com-
posite score consisted of eight measures: CPT-
HQ (average performance index and variance,
the latter being negatively transformed), RST,
WAIS-III Digit Symbol, Block Design, Arithme-
tic, and Information, WLT (average immediate
and delayed recall) and educational degree. For
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clinical symptoms, a mean score was created,
based on the eight PANSS items.
Hierarchical regression analyses investigated the
predictive value of neurocognition, social cogni-
tion, clinical symptoms and phase of illness at
baseline. These variables were entered block-wise,
which enabled us to investigate the explained vari-
ance of neurocognition, as well as the additional
explained variance of social cognition, clinical
symptoms and phase of illness. Age at baseline and
sex were entered in the first block, as covariates.
Scatter plots were used to evaluate the direction of
the effects. Changes  1 SD were considered
insight improvement, whereas changes  1 SD
were considered insight decrease.
Next, we analysed whether changes in neuro-
cognition, social cognition, clinical symptoms and
phase of illness were related to insight change.
This was carried out by subtracting the score at
baseline from the score at follow-up. These
change scores were then transformed into z-scores
to create a composite measure for neurocognition.
Thus, for neurocognition change as well as social
cognition, higher change scores indicated
improved performance; for clinical symptoms
change, higher scores indicated more symptoms.
Variables were entered block-wise in a new regres-
sion analysis, again with the covariates age and
sex in the first block.
All analyses were performed with two-tailed
hypothesis testing, with a = 0.05. For the evalua-
tion of the scaled scores and composite measures,
we allowed for 30% of missing values. Statistical
analyses were performed using PASW 18.0 (PASW
Statistics for Windows, Version 18.0. Chicago, IL,
USA: SPSS Inc., 2009). Release 3.0 of the GROUP
database was used for the analyses. For descriptive
purposes, correlations between all variables are
displayed in Table S1.
Results
Descriptives
Of the 270 patients assessed with the assessment
of insight at baseline, 154 were assessed in
GROUP at follow-up. Drop-out in Utrecht and
Amsterdam was relatively similar (45% and 55%,
respectively). These patients (n = 116) received a
questionnaire to investigate reasons for drop-out;
however, none of these patients responded to this
request. Insight at baseline of the remaining
patients differed significantly from the drop-out
patients [F(1,272) = 12.649, P < 0.001], with the
former having higher levels of insight (z = 0.16,
z = 0.19, respectively). The effect size of this dif-
ference was small (d = 0.46), suggesting that the
sample is still relatively reliable. Differences were
also significant for education [F(1,272) = 7.605,
P = 0.006]. The remaining patient group was
higher educated, as compared to the drop-out
patients. Differences were not significant for neu-
rocognition, social cognition, clinical symptoms,
phase of illness, age and sex. Table 1 shows the
demographic and clinical data for the included
154 patients of the current study. At baseline,
impaired insight defined as PANSS G12  3
(3 = threshold for the presence of a symptom) was
found in 45% of the included patients. On the
BIS, 56% of the patients had a score  9
(9 = threshold for the presence of insight impair-
ment). At baseline, 21% of the patients included
had a recent onset psychosis.
Insight change: relationship with baseline insight
The difference between insight at baseline and fol-
low-up was not statistically significant (P = 0.388).
The relationship between insight at baseline and
insight at follow-up was significant (r = 0.415,
P < 0.001). Furthermore, baseline insight was sig-
nificantly related to insight change (r = 0.515,
Table 1. Baseline characteristics of the patients (N = 154)*
Variable
Assessment
Baseline (T0 years) Follow-up (T3 years)
Age, years 28 (7) 31 (7)
Gender, male % 80 80
Education† 4.6 (2.1) 4.9 (1.9)
Duration of illness, years 5 (5) 7 (5)
Diagnostic
Schizophrenia, % 67 66
Schizo-affective, % 19 18
Psychosis NOS, % 8 5
Other, % 6 11
Anti-psychotics
Olanzapine, % 32 20
Risperidone, % 25 15
Clozapine, % 10 20
Aripiprazol, % 8 16
Quetiapine, % 7 9
Other, % 11 11
No anti-psychotics, % 7 9
PANSS
Positive 1.9 (0.8) 1.6 (0.6)
Negative 2.2 (0.8) 1.7 (0.7)
General 1.8 (0.5) 1.5 (0.4)
Insight
G12 2.0 (1.3) 1.7 (1.2)
BIS 9.3 (2.5) 8.9 (2.7)
*Table presents means (SD) or numbers (in %).
†Education (Verhage): range 0 (no education), 3–5 (school diploma) to 8 (academic
degree).
PANSS, Positive And Negative Syndrome Scale; G12, PANSS item G12 ‘Judgment
and Insight’; BIS, Birchwood Insight Scale.
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P < 0.001), with better insight at baseline being
associated with more insight improvement.
Insight change: relationships with baseline neurocognition, social
cognition, clinical symptoms and phase of illness
Insight change was significantly related to baseline
neurocognition (r = 0.231, P = 0.005) and clinical
symptoms (r = 0.215, P = 0.009). Better baseline
neurocognitive performances were related to
improvements in insight after 3 years (Fig. 1).
Patients with more symptoms at baseline had
decreased insight (Fig. 2). The relationship with
social cognition and phase of illness was non-sig-
nificant. When neurocognition and clinical symp-
toms were entered in the regression analysis
consecutively, with age and sex as covariates, the
additional explained variance of clinical symptoms
was significant. Together, these factors explained
insight improvement for 10% (Table 2).
Insight change: relationships with changes in neurocognition,
social cognition and clinical symptoms
The difference between neurocognition at baseline
and follow-up was statistically significant
(t = 5.941, P < 0.001). This was also true for
clinical symptoms (t = 6.138, P < 0.001), but not
for social cognition (P = 0.155). Better neurocog-
nitive performance and less severe clinical symp-
toms were found at follow-up. Effect sizes were
small for neurocognition (d = 0.25) and in the
medium range for clinical symptoms (d = 0.51).
Insight change was significantly related to change
in clinical symptoms (r = 0.223, P = 0.008).
Decreases in clinical symptoms over time were
related to increases in insight. The relationships
with change in neurocognition, social cognition
and phase of illness were non-significant. When
change in clinical symptoms was entered in the
regression analysis, with age and sex as
covariates, the explained variance of the model
was 12%, with the contribution of clinical symp-
toms being significant (b = 0.324, P < 0.001)
(Table 3).
Discussion
The current study investigated factors associated
with insight change in non-affective psychosis.
Results can be summarized as follows. Most
importantly, we found that, although the mean
group-level of insight was relatively stable over
time, improvement of insight within patients was
positively related to baseline neurocognitive per-
formances and negatively related to baseline symp-
tom severity. In addition, changes in insight were
found to fluctuate with changes in symptom sever-
ity, but not with changes in neurocognition,
between baseline and follow-up.
The course of insight was stable in the majority
of this relatively young population. This is in line
with findings that interventions to date had only
limited success in improving insight over time (28).
It therefore becomes relevant to study the underly-
ing factors of this insight stability. Longitudinal
studies focusing on insight have provided mixed
results (9, 11, 12). Rather than predicting the
future level of insight, our study focused on factors
contributing to changes in insight. The advantage
of this approach is that using a difference score as
the outcome measure, both the level of insight at
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Fig. 1. Insight change as a function of
baseline neurocognition.
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baseline, as well as insight at follow-up are taken
into account.
In line with the hypotheses, baseline neurocogni-
tion substantially contributed to insight change,
together with clinical symptoms. This shows that
neurocognitive impairments may have a limiting
effect on insight. Baseline symptom severity as well
as decreases in symptoms over time was associated
with an increase in insight as well. This may be
explained by the fact that the patients in our sam-
ple improved in terms of clinical symptoms
(d = 0.51). Neurocognitive improvement, on the
other hand, was only small (d = 0.25). Neurocog-
nition may thereby contribute to ‘trait’ character-
istics of insight, whereas clinical symptoms
contribute to ‘state’ characteristics. Possibly, the
current treatments for psychosis are already partly
beneficial to improve state characteristics of insight
in psychosis. In a subsequent analysis, we found
that some of the neurocognitive abilities and clini-
cal symptoms may be particularly responsible for
this (Table S1). The relationship between these
significant variables should be tested in a new
sample to confirm their predictive value on insight
change.
In contrast to our expectations, phase of illness
and social cognition were not related to insight
change. Therefore, insight change may not differ
between recent onset patients and other patients.
On the other hand, it cannot be ruled out that the
correlates of insight change would differ in a study
covering a longer period of time. In an earlier
study, we found social cognition to be of addi-
tional value for insight as well (14). Social cogni-
tion has been found to mediate the relationship
between neurocognition and functional outcome
(29). Neurocognitive impairments may thereby
underlie the deficits in emotion perception and
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Fig. 2. Insight change as a function of
baseline clinical symptoms.
Table 2. Relationships of baseline neurocognition and clinical symptoms with insight change for patients with psychotic disorders
Model
Insight change (T0 years–T3 years)
df bCognition bclinical symptoms P F R R
2 PChange FChange R
2
Change
Neurocognition 3,137 0.259* – 0.018 3.450 0.265 0.070 – – –
+ Clinical symptoms 4,136 0.200† 0.176† 0.007 3.660 0.312 0.097 0.046 4.061 0.027
b = standardized beta coefficient; Pchange, Fchange, Rchange, and R
2
change refer to the statistical significance of the model as compared with its preceding model.
*Correlation significant at the 0.01 level. Included covariates are age and sex.
†Correlation significant at the 0.05 level.
Table 3. Relationships of changes in clinical symptoms with insight change for
patients with psychotic disorders
Model
Insight change (T0 years – T3 years)
df
bClinical
symptoms P F R R
2
Change in clinical
symptoms
3,138 0.343† 0.001 6.087 0.342 0.117
b = standardized beta coefficient.
†Correlation significant at the 0.01 level. Included covariates are age and sex.
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theory of mind, and this may also apply to the
enduring impairments in insight.
The current study may have clinical implica-
tions. It has been suggested that patients with more
severe neurocognitive impairments are less able to
profit from psychosocial interventions (30). This
may also explain why they only minimally improve
insight. Such interventions may need to be
provided with a high level of structure, and more
rehearsal, to improve insight. We did not find a
relationship between neurocognitive change and
insight change. Still, this does not rule out a role of
cognitive remediation here. Enhanced cognition,
together with decreased symptoms may give the
patients more possibilities to increase their aware-
ness of illness over time.
Strengths of the current study were its longitu-
dinal design, the assessment of several cognitive
domains and the methodology used. Some limi-
tations should also be considered. First, a sub-
stantial subgroup did not participate in the
GROUP study at follow-up. Although effect
sizes were small, patients who did not participate
at follow-up study had poorer insight at base-
line. Reasons for drop-out were unknown. Sec-
ond, our assessment of social cognition was
limited. We did not include a measure of meta-
cognition, which may be more closely related to
insight (31). Third, stigma and depressive symp-
toms were not assessed in the current study (32–
34). Fourth, the assessment of insight may have
been more comprehensive would we have used
the Structured Assessment of Insight-Expanded
(34). It cannot be ruled out that this would had
changed the level of insight at baseline, and the
contribution of social cognition to insight change
which was non-significant in the current study.
Due to these limitations our results should be
interpreted cautiously.
In conclusion, the current study highlights the
role of neurocognition and clinical symptoms for
insight improvement. Therefore, it may be neces-
sary to develop treatment strategies that incorpo-
rate these aspects, among others such as stigma,
metacognition and depressive symptoms (35).
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